Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2017

Open Access 01-12-2017 | Primary research

PI3Kα isoform-dependent activation of RhoA regulates Wnt5a-induced osteosarcoma cell migration

Authors: Ailiang Zhang, Ting Yan, Kun Wang, Zhihui Huang, Jinbo Liu

Published in: Cancer Cell International | Issue 1/2017

Login to get access

Abstract

Background

We have reported that the phosphatidylinositol-3 kinase (PI3K)/Akt signaling pathway mediated Wnt5a-induced osteosarcoma cell migration. However, the signaling pathways regulating Wnt5a/PI3K/Akt-mediated cell migration remains poorly defined in osteosarcoma cells.

Methods

We evaluated the activations of RhoA, Rac1 and Cdc42 in osteosarcoma MG-63 and U2OS cells with small G-protein activation assay. Boyden chamber assays were used to confirm the migration of cells transfected indicated constructs or siRNA specific against RhoA. A panel of inhibitors of PI3K and Akt treated osteosarcoma cells and blocked kinase activity. Western blotting and RhoA activation assay were employed to measure the effect of kinase inhibitors and activations of RhoA and Akt.

Results

We found that Wnt5a had a potent stimulatory effect on RhoA activation, but not on Rac1 and Cdc42 activations. Wnt5a-induced cell migration was largely abolished by siRNA specific against RhoA. DN-RhoA (GFP-RhoA-N19) was also capable of retarding Wnt5a-induced cell migration, but the overexpression of CA-RhoA (GFP-RhoA-V14) was not able to accelerate cell migration. The Wnt5a-induced activation of RhoA was mostly blocked by pretreatment of LY294002 (PI3K inhibitor) and MK-2206 (Akt inhibitor). Furthermore, we found that the Wnt5a-induced activation of RhoA was mostly blocked by pretreatment of HS-173 (PI3Kα inhibitor). Lastly, the phosphorylation of Akt (p-Ser473) was not altered by transfection with siRNA specific against RhoA or DN-RhoA (GFP-RhoA-N19).

Conclusions

Taken together, we demonstrate that RhoA acts as the downstream of PI3K/Akt signaling (specific PI3Kα, Akt1 and Akt2 isoforms) and mediated Wnt5a-induced the migration of osteosarcoma cells.
Appendix
Available only for authorised users
Literature
1.
Ren L, et al. The actin-cytoskeleton linker protein ezrin is regulated during osteosarcoma metastasis by PKC. Oncogene. 2009;28(6):792–802.CrossRefPubMed
2.
Khanna C, et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med. 2004;10(2):182–6.CrossRefPubMed
3.
4.
Lehtimaki J, Hakala M, Lappalainen P. Actin filament structures in migrating cells. Handb Exp Pharmacol. 2016;235:123–52.CrossRef
5.
Littlefield R, Almenar-Queralt A, Fowler VM. Actin dynamics at pointed ends regulates thin filament length in striated muscle. Nat Cell Biol. 2001;3(6):544–51.CrossRefPubMed
6.
Genova JL, et al. Functional analysis of Cdc42 in actin filament assembly, epithelial morphogenesis, and cell signaling during Drosophila development. Dev Biol. 2000;221(1):181–94.CrossRefPubMed
7.
Chang E, et al. MK2 SUMOylation regulates actin filament remodeling and subsequent migration in endothelial cells by inhibiting MK2 kinase and HSP27 phosphorylation. Blood. 2011;117(8):2527–37.CrossRefPubMedPubMedCentral
8.
Tsuji T, et al. Involvement of p114-RhoGEF and Lfc in Wnt-3a- and dishevelled-induced RhoA activation and neurite retraction in N1E − 115 mouse neuroblastoma cells. Mol Biol Cell. 2010;21(20):3590–600.CrossRefPubMedPubMedCentral
9.
Kim GH, Han JK. JNK and ROKalpha function in the noncanonical Wnt/RhoA signaling pathway to regulate Xenopus convergent extension movements. Dev Dyn. 2005;232(4):958–68.CrossRefPubMed
10.
Chen WD, et al. RhoA-Rho kinase signaling pathway mediates adventitial fibroblasts differentiation to myofibroblasts induced by TGF-beta1. Sheng Li Xue Bao. 2013;65(2):113–21.PubMed
11.
12.
Banyard J, et al. Motility and invasion are differentially modulated by Rho family GTPases. Oncogene. 2000;19(4):580–91.CrossRefPubMed
13.
Keely PJ, et al. Cdc42 and Rac1 induce integrin-mediated cell motility and invasiveness through PI(3)K. Nature. 1997;390(6660):632–6.CrossRefPubMed
14.
Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol. 2004;20:781–810.CrossRefPubMed
15.
Zhu N, et al. Challenging role of Wnt5a and its signaling pathway in cancer metastasis (Review). Exp Ther Med. 2014;8(1):3–8.PubMedPubMedCentral
16.
Zhang A, et al. Wnt5a promotes migration of human osteosarcoma cells by triggering a phosphatidylinositol-3 kinase/Akt signals. Cancer Cell Int. 2014;14(1):15.CrossRefPubMedPubMedCentral
17.
Liu J, et al. PI3 K/Akt-dependent phosphorylation of GSK3beta and activation of RhoA regulate Wnt5a-induced gastric cancer cell migration. Cell Signal. 2013;25(2):447–56.CrossRefPubMed
18.
Asem, M.S., et al., Wnt5a Signaling in Cancer. Cancers (Basel), 2016. 8(9).
19.
Leris AC, et al. WNT5A expression in human breast cancer. Anticancer Res. 2005;25(2A):731–4.PubMed
20.
21.
Takiguchi G, et al. Wnt5a-Ror2 signaling in mesenchymal stem cells promotes proliferation of gastric cancer cells by activating CXCL16-CXCR6 axis. Cancer Sci. 2016;107(3):290–7.CrossRefPubMedPubMedCentral
22.
23.
Linnerth-Petrik NM, et al. Akt isoform specific effects in ovarian cancer progression. Oncotarget. 2016;7:74820–33.PubMed
24.
Yang ZZ, et al. Physiological functions of protein kinase B/Akt. Biochem Soc Trans. 2004;32(Pt 2):350–4.CrossRefPubMed
25.
Aifuwa I, et al. Senescent stromal cells induce cancer cell migration via inhibition of RhoA/ROCK/myosin-based cell contractility. Oncotarget. 2015;6(31):30516–31.PubMedPubMedCentral
Metadata
Title
PI3Kα isoform-dependent activation of RhoA regulates Wnt5a-induced osteosarcoma cell migration
Authors
Ailiang Zhang
Ting Yan
Kun Wang
Zhihui Huang
Jinbo Liu
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2017
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-017-0396-8

Other articles of this Issue 1/2017

Cancer Cell International 1/2017 Go to the issue

Primary Research

Erythropoietin promoted the proliferation of hepatocellular carcinoma through hypoxia induced translocation of its specific receptor

Primary research

MiR–20a-5p promotes radio-resistance by targeting Rab27B in nasopharyngeal cancer cells

Primary Research

ROR2 receptor promotes the migration of osteosarcoma cells in response to Wnt5a

Primary research

Overexpression of suppressor of zest 12 is associated with cervical node metastasis and unfavorable prognosis in tongue squamous cell carcinoma

Primary Research

pATM and γH2AX are effective radiation biomarkers in assessing the radiosensitivity of 12C6+ in human tumor cells

Correction

Correction to: The role of pparγ and autophagy in ros production, lipid droplets biogenesis and its involvement with colorectal cancer cells modulation
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits